Description
Arthritis is one of the most common human ailments worldwide. Arthritis is a complex family of musculoskeletal disorders with many causes that are not fully understood. The most crippling of the arthritis family is rheumatoid arthritis, which is an autoimmune disease. Successful treatment of arthritis has resulted from a growing array of therapies available to physicians.
While these pharmaceutical products are still used regularly, new disease-modifying therapies have produced the most impressive results in treating more severe types of arthritis. Additionally, combination therapies continue to grow in preference and offer exciting results in disease management.
This Kalorama Information report, The World Market for Prescription Arthritis Treatments, details the market for these treatments. The report provides market sizes and forecasts for the following categories of treatments:
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Biologic Response Modifiers (BRMs) and Immunosuppressants
For each category, the report breaks down the regional market (US, Europe, Japan, Rest of World), lists major products, and provides market share among major competitors.
There are several issues and trends that are shaping this market. Some of the topics, discussed in this report include:
- US Economic Impact of Arthritis
- World Economic Impact of Arthritis
- Obesity and Arthritis
- Trends in Insurance and Reimbursement
- Threat to Anti-TNF Dominance
- ADAM-12 Gene Discovery
- New Pricing Structure in Germany
The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the worldwide arthritis treatment market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 20 industry executives and product managers to validate and obtain expert opinion on current and future trends in the worldwide prescription arthritis treatment market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
The following companies are profiled in the report:
- Abbott Laboratories
- Amgen, Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- Galapagos NV
- Genentech, Inc.
- Horizon Pharma
- Janssen Biotech, Inc
- Novartis International AG
- Pfizer, Inc.
- Roche
- Regeneron
- UCB
All market data pertains to the worldwide market at the manufacturers’ level. Data are expressed in current U.S. dollars. A geographic breakdown is also included for US, Europe, Japan and Rest of World total market and in each drug type segment. The base year for data was 2011. Historical data are provided for each of the years 2009 to 2011, and forecast data are provided for each of the years 2011 through 2016. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2011 base year.
All Kalorama Information reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
For Kalorama’s take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information’s Key Point Blog at http://kaloramakeypoint.blogspot.com/
